Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 9/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | TACR2 | P21452 | 5/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481910 | 0.90 | CNR2 (0.61) | CNR2TACR1TACR2P2RX7 | |
| SCHEMBL4481017 | 0.88 | CNR2 (0.53) | CNR2LMNASMN1; SMN2TACR1PTGDR2 | |
| SCHEMBL4472734 | 0.88 | CNR2 (0.59) | CNR2TACR1TACR2P2RX7 | |
| SCHEMBL4471532 | 0.88 | CNR2 (0.59) | CNR2TACR1PTGDR2TACR2P2RX7 | |
| SCHEMBL13708840 | 0.87 | CNR2 (0.53) | CNR2LMNASMN1; SMN2PTGDR2 | |
| SCHEMBL4475464 | 0.87 | CNR2 (0.53) | CNR2LMNASMN1; SMN2PTGDR2 | |
| SCHEMBL4477211 | 0.87 | CNR2 (0.58) | CNR2TACR1TACR2P2RX7 | |
| SCHEMBL4476258 | 0.87 | CNR2 (0.58) | CNR2TACR1TACR2P2RX7 | |
| SCHEMBL4475466 | 0.87 | CNR2 (0.53) | CNR2LMNASMN1; SMN2PTGDR2 | |
| SCHEMBL4471995 | 0.85 | CNR2 (0.56) | CNR2SMN1; SMN2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | CNR2 2/4885LMNA 3602/4885SMN1; SMN2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.